Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changing Role of Adjuvant Therapy in Stage III Melanoma.

The New England journal of medicine·2025
Same author

Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.

Melanoma research·2025
Same author

A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.

Cancer journal (Sudbury, Mass.)·2024
Same author

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.

Cancer research communications·2023
Same journal

Revisiting Stability: The Missing Therapeutic Endpoint in Active Vitiligo Trials.

Pigment cell & melanoma research·2026
Same journal

Multi-Omics Identifies CTSS as a Susceptibility Gene and Actionable Target That Regulates Melanocyte MHC-II Expression and Survival in Vitiligo.

Pigment cell & melanoma research·2026
Same journal

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

Pigment cell & melanoma research·2026
Same journal

Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan-Induced DNA Double-Strand Breaks in Uveal Melanoma.

Pigment cell & melanoma research·2026
Same journal

MelOD: The Melanoma Omics Dashboard for Multimodal Data Exploration.

Pigment cell & melanoma research·2026
Same journal

Genetic Analysis of Acral Melanomas From Southern African Patients.

Pigment cell & melanoma research·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Programming T cells for adoptive T cell transfer therapy

Paul B Chapman

    Pigment Cell & Melanoma Research
    |February 5, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
    07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019

    Related Experiment Videos

    Last Updated: May 8, 2026

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
    12:55

    Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

    Published on: February 16, 2015

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
    07:25

    Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

    Published on: September 25, 2019